Telo Genomics Current Ratio vs. Cash Flow From Operations

TDSGF Stock  USD 0.08  0  1.23%   
Based on Telo Genomics' profitability indicators, Telo Genomics Corp may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Telo Genomics' ability to earn profits and add value for shareholders.
For Telo Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Telo Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Telo Genomics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Telo Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Telo Genomics Corp over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Telo Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Telo Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telo Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Telo Genomics Corp Cash Flow From Operations vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Telo Genomics's current stock value. Our valuation model uses many indicators to compare Telo Genomics value to that of its competitors to determine the firm's financial worth.
Telo Genomics Corp is currently regarded as top stock in current ratio category among its peers. It is rated third in cash flow from operations category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telo Genomics' earnings, one of the primary drivers of an investment's value.

Telo Cash Flow From Operations vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Telo Genomics

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
14.66 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Telo Genomics

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(1.79 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

Telo Cash Flow From Operations Comparison

Telo Genomics is currently under evaluation in cash flow from operations category among its peers.

Telo Genomics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Telo Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Telo Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Telo Genomics' change in net profit over the period of time. It can combine multiple indicators of Telo Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada. TELO GENOMICS is traded on OTC Exchange in the United States.

Telo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Telo Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Telo Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Telo Genomics' important profitability drivers and their relationship over time.

Use Telo Genomics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telo Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telo Genomics will appreciate offsetting losses from the drop in the long position's value.

Telo Genomics Pair Trading

Telo Genomics Corp Pair Trading Analysis

The ability to find closely correlated positions to Telo Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telo Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telo Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telo Genomics Corp to buy it.
The correlation of Telo Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telo Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telo Genomics Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telo Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Telo Genomics position

In addition to having Telo Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Technology Thematic Idea Now

Technology
Technology Theme
Companies that are involved in development or distribution of technologically based goods and services such as software, IT or electronics. The Technology theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Technology Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Telo OTC Stock

To fully project Telo Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Telo Genomics Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Telo Genomics' income statement, its balance sheet, and the statement of cash flows.
Potential Telo Genomics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Telo Genomics investors may work on each financial statement separately, they are all related. The changes in Telo Genomics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Telo Genomics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.